CTOs on the Move

ADM Benefit Plans Agency

www.admbenefits.com

 
ADM Benefit Plans Agency is a Bucyrus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

MorganWhiteGroup

John J. Morgan and David R. White founded MorganWhiteGroup, Inc. in 1987. The business started out primarily focusing on payroll deduction of supplemental insurance products, and has grown into what is today, a holding company made up of 6 wholly owned subsidiaries.    The MorganWhiteGroup of companies now includes: Two sales agencies, MWG Employer Services and MWG Senior Healthcare, two third-party administrators (TPAs), MorganWhite Administrators, Inc. and MorganWhite Administrators International, a marketing agency, MWG Marketing, and a Reinsurance Intermediary, MWG Reinsurance, Inc.   Our success since 1987 has been achieved by delivering insurance products to the marketplace that cannot be found anywhere else. Our company's guiding principal has been to find a market that is either under-served or not served at all and design a product to fit that market.   At MorganWhiteGroup, we look forward to the challenge of solving customers’ medical, dental and vision insurance needs today, and in the future. We are committed to making the investment in technology, equipment, and personnel to provide our customers with the latest, most up to date tools available, to solve their insurance needs.

ODA Primary Health Care Center

ODA Primary Health Care Center is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Wellington Place

Wellington Place is a North Olmsted, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Taris Biomedical

Taris Biomedical is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Wave Life Sciences

WAVE Life Sciences is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering exceptional treatment options for patients. Given the unique versatility of its chemistry platform, WAVE`s pipeline will span multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi.